Eisai Co Ltd
TSE:4523
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4 619
7 776
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Eisai Co Ltd stock under the Base Case scenario is 7 322.83 JPY. Compared to the current market price of 4 650 JPY, Eisai Co Ltd is Undervalued by 36%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Eisai Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Eisai Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Eisai Co Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Eisai Co., Ltd., founded in 1941 and headquartered in Tokyo, Japan, stands as a prominent global player in the pharmaceutical industry, dedicated to research and development in areas such as neurology and oncology. With a mission encapsulated in their philosophy of "human health care" (hhc), Eisai strives not only for profit but also for the well-being of patients, positioning itself as a company that deeply values purpose alongside its financial goals. Over the years, Eisai has gained recognition for its innovative products, particularly the Alzheimer's treatment, Aricept, which has generated a substantial portion of its revenue. Investors might find this focus on neurodegenerative diseases...
Eisai Co., Ltd., founded in 1941 and headquartered in Tokyo, Japan, stands as a prominent global player in the pharmaceutical industry, dedicated to research and development in areas such as neurology and oncology. With a mission encapsulated in their philosophy of "human health care" (hhc), Eisai strives not only for profit but also for the well-being of patients, positioning itself as a company that deeply values purpose alongside its financial goals. Over the years, Eisai has gained recognition for its innovative products, particularly the Alzheimer's treatment, Aricept, which has generated a substantial portion of its revenue. Investors might find this focus on neurodegenerative diseases particularly compelling, given the aging global population and the increasing prevalence of conditions like Alzheimer's.
Eisai's commitment to innovation is complemented by strategic partnerships and collaborations, including notable alliances with big biotech and pharmaceutical companies, enhancing its research capabilities and market reach. With a firm commitment to sustainability and environmental issues, the company not only focuses on profitability but also adheres to a long-term vision that resonates with contemporary investment ideals. As Eisai moves forward, its pipeline of products, including promising cancer therapies, offers investors a glimpse into its growth potential and the company's adaptability within a rapidly changing healthcare landscape. This combination of ethical responsibility, strategic growth, and market relevance positions Eisai as an intriguing prospect for investors searching for both stability and potential in the pharmaceutical sector.
Eisai Co., Ltd. is a Japanese pharmaceutical company that focuses on the research, development, manufacturing, and marketing of innovative pharmaceuticals. Its core business segments can be categorized primarily as follows:
-
Pharmaceuticals:
- Neurology: Eisai is well known for its products in the neurology segment, particularly in areas such as Alzheimer's disease. The company's flagship medication, Aricept (donepezil), is widely used for the treatment of Alzheimer's symptoms.
- Oncology: The oncology segment has been a growing focus for Eisai, with products aimed at treating various types of cancers. Lenvatinib, an oral kinase inhibitor, has gained significant traction for treating multiple tumor types, including thyroid cancer and hepatocellular carcinoma.
- Gastroenterology: Eisai also develops drugs for gastrointestinal disorders, with a particular emphasis on medications for conditions like non-alcoholic steatohepatitis (NASH) and irritable bowel syndrome (IBS).
-
Consumer Healthcare:
- Eisai has a segment dedicated to over-the-counter (OTC) products, which includes dietary supplements and other health-related products. This segment aims to provide consumer solutions for self-care and well-being.
-
Biopharmaceuticals:
- The company invests in the development of biologics and advanced therapies, including antibody-drug conjugates (ADCs) and biosimilars, to target various diseases, particularly in oncology.
-
Research and Development:
- R&D is a crucial pillar of Eisai’s business model. The company places a strong emphasis on innovation, investing heavily in drug discovery and development to identify new treatments, particularly in areas of unmet medical need, like neurology and oncology.
-
Global Operations:
- Eisai operates on a global scale, with a presence in multiple regions including North America, Europe, and Asia. This international reach allows Eisai to maximize its market opportunities across different regulatory environments and healthcare systems.
Eisai's strategy often focuses on collaboration, partnerships, and licensing agreements to enhance its pipeline and market reach, while maintaining a commitment to addressing the needs of patients worldwide.
Eisai Co., Ltd. possesses several competitive advantages in the pharmaceutical industry that differentiate it from its rivals. Here are some key points:
-
Focus on Neuroscience:
- Eisai specializes in neuroscience and has established a strong portfolio in treating central nervous system disorders, particularly Alzheimer's disease. This focus enables them to build deep expertise and innovate in a niche market.
-
Strong R&D Capabilities:
- The company invests heavily in research and development. Eisai’s commitment to innovation has led to the development of several significant drugs, including treatments for epilepsy and Alzheimer's. Their robust pipeline positions them well to address ongoing and emerging health challenges.
-
Collaborative Partnerships:
- Eisai often collaborates with other pharmaceutical companies, academic institutions, and research organizations, enhancing its capacity for innovation and expanding its reach in drug development.
-
Global Network:
- With a presence in various markets, including Asia, Europe, and North America, Eisai can leverage global trends and markets, allowing for more diverse revenue streams and risk mitigation.
-
Patient-Centric Approach:
- Eisai emphasizes a patient-first philosophy, which drives their development processes and market strategies. This approach not only helps in drug development that directly addresses patient needs but also strengthens brand loyalty and company reputation.
-
Established Brand Trust:
- With a history dating back to 1941, Eisai has built a recognized and trusted brand in the pharmaceutical sector, which is crucial for customer loyalty, partnerships, and ultimately sales.
-
Regulatory Expertise:
- Given their extensive experience in the industry, Eisai has developed strong capabilities to navigate regulatory landscapes across different regions, facilitating quicker and more efficient approvals for their products.
-
Diverse Product Line:
- Besides neuroscience, Eisai has a diverse product lineup that includes oncology and other therapeutic areas. This diversification allows the company to offset risks associated with any single product or therapeutic area.
-
Sustainability and Corporate Citizenship:
- Eisai is committed to sustainability and corporate social responsibility, which can enhance its corporate image and align with consumers’ increasing preference for ethically responsible companies.
These competitive advantages help Eisai not only to stand out among its peers but also to maintain resilience in a highly competitive and regulated industry.
Eisai Co., Ltd., a Japanese pharmaceutical company, faces several risks and challenges in the near future. Here are some key considerations:
-
Market Competition: The pharmaceutical industry is highly competitive, with many companies developing similar products. Eisai needs to effectively differentiate its products, especially in areas like oncology and neurology, where competition is intense.
-
Regulatory Challenges: Compliance with regulatory requirements in various regions (such as the FDA in the U.S. and EMA in Europe) can be complex and time-consuming. Any delays or issues in obtaining drug approvals can impact revenue and innovation timelines.
-
Research and Development Risks: The success of new drugs is uncertain. High research and development costs combined with a lengthy approval process mean that setbacks can significantly affect financial performance.
-
Patent Expiry and Generic Competition: As patents for key products expire, Eisai may face increased pressure from generic competitors that can influence market share and pricing power.
-
Global Economic Factors: Economic downturns, fluctuations in currency exchange rates, and changes in healthcare policies can affect demand for Eisai's products and impact financial stability.
-
Supply Chain Disruptions: Global supply chain issues can lead to delays in production, increased costs, or shortages of raw materials, affecting the ability to meet market demand.
-
Pricing Pressure: Rising scrutiny over drug pricing, especially in the U.S., and potential regulatory changes may lead to pricing pressure that impacts profitability.
-
Technological Changes: Rapid advancements in medical technology and pharmaceuticals may require Eisai to continuously innovate to stay competitive or risk becoming obsolete.
-
Mergers and Acquisitions: As the industry consolidates, Eisai may face challenges in integrating acquisitions, and competing with larger entities with greater resources can be a long-term threat.
-
Public Health Crises: Events such as pandemics can disrupt operations, alter healthcare priorities, and shift focus away from chronic disease management, which may affect sales and developmental focus.
-
Data Privacy and Cybersecurity Risks: With an increasing reliance on digital technologies, Eisai must ensure the security of its data, protecting against breaches that could lead to loss of sensitive information and involve significant recovery costs.
-
Changing Consumer Behavior: The expectations and behaviors of healthcare providers and patients are evolving, which may require Eisai to adjust its marketing strategies, product offerings, and customer engagement approaches.
By addressing these challenges proactively, Eisai can navigate the complex landscape of the pharmaceutical sector while striving for sustainable growth.
Revenue & Expenses Breakdown
Eisai Co Ltd
Balance Sheet Decomposition
Eisai Co Ltd
Current Assets | 733.2B |
Cash & Short-Term Investments | 304.9B |
Receivables | 205.4B |
Other Current Assets | 223B |
Non-Current Assets | 687B |
Long-Term Investments | 59.6B |
PP&E | 165.4B |
Intangibles | 334.3B |
Other Non-Current Assets | 127.8B |
Current Liabilities | 311B |
Accounts Payable | 77.8B |
Other Current Liabilities | 233.2B |
Non-Current Liabilities | 213.5B |
Long-Term Debt | 134.8B |
Other Non-Current Liabilities | 78.7B |
Earnings Waterfall
Eisai Co Ltd
Revenue
|
733.8B
JPY
|
Cost of Revenue
|
-151.2B
JPY
|
Gross Profit
|
582.7B
JPY
|
Operating Expenses
|
-541.9B
JPY
|
Operating Income
|
40.8B
JPY
|
Other Expenses
|
-8.1B
JPY
|
Net Income
|
32.6B
JPY
|
Free Cash Flow Analysis
Eisai Co Ltd
JPY | |
Free Cash Flow | JPY |
Eisai reported a Q2 FY2024 revenue increase of 3% year-on-year, totaling JPY 385 billion, driven primarily by a 5% growth in the pharmaceutical segment, notably from LEQEMBI, which saw a JPY 15.9 billion rise. However, operating profit declined to JPY 27.8 billion (down 13%), with SG&A costs up due to market expansion efforts. LEQEMBI aims for U.S. profitability by FY2026, while Japan and China expect breakeven in FY2025. Total annual revenues are projected at JPY 42.5 billion, highlighting the challenge of managing infusion capacity against rising demand.
What is Earnings Call?
Profitability Score
Profitability Due Diligence
Eisai Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Eisai Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Eisai Co Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Score
Eisai Co Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Eisai Co Ltd
According to Wall Street analysts, the average 1-year price target for Eisai Co Ltd is 7 242.36 JPY with a low forecast of 4 646 JPY and a high forecast of 10 185 JPY.
Dividends
Current shareholder yield for Eisai Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. The company is headquartered in Bunkyo-Ku, Tokyo-To and currently employs 11,237 full-time employees. The firm operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The firm is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
Contact
IPO
Employees
Officers
The intrinsic value of one Eisai Co Ltd stock under the Base Case scenario is 7 322.83 JPY.
Compared to the current market price of 4 650 JPY, Eisai Co Ltd is Undervalued by 36%.